Brandon G. Smaglo

Nov 21, 2024 | onclive.com | Brandon G. Smaglo

CommentaryVideoNovember 21, 2024Supplements and Featured PublicationsPancreatic Cancer Awareness Month: Updates in Ongoing Research in RAS InhibitionVolume1 Issue 1Author(s):Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer. In pancreatic cancer, [approximately] 80% to 90% of patients will have a mutation somewhere in KRAS. [These mutations are common enough] that it makes a lot of sense to chase down [these targeted therapies].

Feb 2, 2024 | nature.com | Abdelrahman MG Yousef |Mahmoud Yousef |Saikat Chowdhury |Mark Knafl |Brandon G. Smaglo |Jason Willis | +3 more

AbstractThe relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation status and subtypes were prognostic (p < 0.001).